KeriMedical

BOOTH 707. ASSH 2026. Following an exciting first year in the United States, KeriMedical is proud to return to the ASSH in Boston. Visit Booth 707 to discover how the TOUCH® Dual Mobility CMC 1 System is helping surgeons rethink thumb arthroplasty through clinical expertise, innovative implant design, and a growing digital ecosystem. Meet our international team and connect with leading CMC 1 experts : 📍 Boston, MA 📅 September 17–19, 2026 📍 Booth 707 See you in Boston. #ASSH2026 #KeriMedical #TOUCHProsthesis #ThumbArthroplasty #CMCArthroplasty #HandSurgery #MedicalDevices #DigitalSurgery #TOUCHXR

Missed the symposium? Do not miss the science. The scientific program from the 2nd International Symposium on CMC 1 Prosthesis is now available through our Replay Library. Revisit expert lectures, clinical discussions and case-based learning shared by an international faculty during two days dedicated to thumb arthroplasty. Whether you attended the symposium or couldn't join us in Nice, you can now access the complete Replay Library on demand. Full access to all available symposium presentations Replay available until June 30, 2027 €70 – One-time payment Request your access: www.cmc1symposium.com #CMC1 #HandSurgery #ThumbArthroplasty #MedicalEducation #KeriAcademy #ScientificExchange

A new milestone for KeriMedical. The inauguration of our expanded Archamps facility marks an important step in our journey—and a special one as we celebrate KeriMedical’s 10th anniversary. In just over a decade, Dougal Bendjaballah, bernard prandi, and Julie MOTTET transformed a vision into a globally recognized company. Starting from the ground up, driven by the belief that hand surgery deserved innovative solutions, they built—together with their teams—a company that is now improving the lives of patients around the world. This expansion reflects our continued growth, but it is not a finish line. It is another step forward, opening the door to the next chapter of innovation and development. We would like to sincerely thank everyone who joined us for this special occasion, especially Matthias Schupp, CEO of Medartis, Vice President of the French Senate Loïc Hervé, Member of Parliament Virginie Duby-Muller, Senator Cyril Pellevat, the representatives of the City of Archamps, Bpifrance and ArchParc, as well as all of our partners, customers, and collaborators. A heartfelt thank you also goes to all our employees, whose passion, commitment, and dedication have made this journey possible. This achievement belongs to every member of the KeriMedical team. Together, we look forward to writing the next chapter of the KeriMedical story. #MedartisGroup #KeriMedical #Innovation #MedTech #HandSurgery #Manufacturing #Teamwork #10Years #Growth

Every patient is different. The solution should be too. The TOUCH® Range offers a comprehensive approach to thumb osteoarthritis treatment, built on the proven dual mobility trapeziometacarpal prosthesis concept and designed to address different patient profiles. TOUCH® STANDARD - The trusted choice for everyday practice. TOUCH® TITANIUM - Designed for patients with metal sensitivities. TOUCH® PLUS - A new solution for younger or highly active patients. All three options feature highly cross-linked Vitamin E enriched polyethylene and the benefits of dual mobility technology. Three options. Three patient profiles. One trusted concept.   *EU ONLY : TOUCH® PLUS will be available upon completion of your domestic applicable regulatory requirements. Please contact your local sales representative for more information. #TOUCH #ThumbOsteoarthritis #HandSurgery #CMC1 #ThumbArthroplasty #KeriMedical

A major milestone for Australian patients and hand surgeons. We are proud to announce that the TOUCH® CMC 1 Prosthesis has been granted a listing on Australia's Prescribed List, effective 1 July 2026. For more than a decade, the TOUCH® prosthesis has helped patients across Europe regain thumb function and improve their quality of life. Thanks to this listing, Australian patients will now have access to the same proven technology for the treatment of thumb osteoarthritis (rhizarthrosis). TOUCH® is a dual-mobility trapeziometacarpal prosthesis designed to relieve pain, restore mobility, and preserve the trapezium bone. This achievement marks an important step in expanding access to innovative solutions for patients suffering from thumb osteoarthritis and reinforces our commitment to advancing hand surgery worldwide. #HandSurgery #ThumbOsteoarthritis #Rhizarthrosis #CMC1 #KeriMedical #ThumbArthroplasty

FESSH 2026 has been an incredible opportunity to connect, exchange, and innovate. Thank you to everyone who visited our booth, attended our symposium, and shared these inspiring days with us. Your interest, feedback, and discussions continue to drive our commitment to advancing CMC 1 joint reconstruction. Beyond the scientific sessions and exhibitions, we were proud to see five KeriMedical team members take part in the Medartis Charity Bike in support of Mercy Ships, helping to raise 15,227 CHF to improve access to surgical care around the world. As we close this edition of FESSH 2026, we are also opening a new chapter for the TOUCH® : we were proud to introduce TOUCH® PLUS, the latest evolution of our range, alongside our established TOUCH® Titanium and TOUCH® Standard solutions. We are excited to share more about this new addition in the coming weeks. The future of CMC joint reconstruction continues... Stay tuned. #FESSH2026 #HandSurgery #KeriMedical #TOUCH #TOUCHPLUS #CMCSurgery #MedicalInnovation #MedTech

🚨 Big milestone alert for TOUCH® CMC 1 Prosthesis in the U.S.! 🚨 KeriMedical (Medartis Group) has officially launched its first U.S. clinical study—and we’re proud to share that the first patient was successfully enrolled on March 23 at Indiana Hand to Shoulder Center (OrthoIndy) in Indianapolis. 👏 A huge congratulations to Dr. F Thomas D Kaplan and Dr. Brandon Smetana for leading the way on this important work! This study marks the beginning of a 163-patient post-approval commitment to the FDA, helping us better understand outcomes like pain reduction and functional improvement over time. More importantly, it represents a meaningful step forward for patients living with thumb arthritis—bringing us closer to redefining treatment options in the U.S. 💬 As Dr. Kaplan put it: this research has the potential to create a “paradigm shift” in how we treat CMC arthritis—similar to the evolution we saw with joint replacement in other areas. 👏 Thank you to: ◼ The clinical study team ◼ Our partners at MCRA (IQVIA business) ◼ And the patients contributing to advancing care This is just the beginning—and we’re excited for what’s ahead. 📖 Read more about this milestone in the official press release: https://lnkd.in/gn3ABPrt #TOUCH #KeriMedical #CMCArthroplasty #ClinicalResearch #MedTech #Orthopedics #InnovationInHand #HealthcareInnovation #PatientCare